Carregant...
To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
ABSTRACT: In addition to the general clinical benefit offered, biosimilars may not only generate savings for healthcare budgets but also improve patient access to biologic products. Since the first biosimilar was approved in Europe in 2006, a further 36 different biosimilar drugs have been approved...
Guardat en:
| Publicat a: | Adv Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Healthcare
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6096951/ https://ncbi.nlm.nih.gov/pubmed/29873005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-018-0719-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|